No connection

Search Results

MRVI vs STAA

MRVI
Maravai LifeSciences Holdings, Inc.
NEUTRAL
Price
$3.28
Market Cap
$1.21B
Sector
Healthcare
AI Confidence
80%
STAA
STAAR Surgical Company
BEARISH
Price
$25.08
Market Cap
$1.24B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
MRVI
--
STAA
--
Forward P/E
MRVI
-21.61
STAA
32.57
P/B Ratio
MRVI
2.25
STAA
3.6
P/S Ratio
MRVI
6.49
STAA
5.19
EV/EBITDA
MRVI
-10.63
STAA
-29.2

Profitability

Gross Margin
MRVI
19.21%
STAA
76.19%
Operating Margin
MRVI
-39.36%
STAA
-18.87%
Profit Margin
MRVI
-70.41%
STAA
-33.6%
ROE
MRVI
-48.59%
STAA
-21.7%
ROA
MRVI
-8.83%
STAA
-5.95%

Growth

Revenue Growth
MRVI
-11.8%
STAA
18.1%
Earnings Growth
MRVI
--
STAA
--

Financial Health

Debt/Equity
MRVI
0.98
STAA
0.11
Current Ratio
MRVI
6.6
STAA
4.55
Quick Ratio
MRVI
5.4
STAA
3.53

Dividends

Dividend Yield
MRVI
--
STAA
--
Payout Ratio
MRVI
0.0%
STAA
0.0%

AI Verdict

MRVI NEUTRAL

MRVI presents a contradictory profile characterized by a stable Piotroski F-Score of 4/9 and exceptional short-term liquidity (Current Ratio 6.60), yet plagued by severe long-term value destruction (-91% 5Y change). While the company is showing signs of an earnings bottom with a 77.8% YoY EPS improvement, the fundamental top-line growth is negative (-11.8% YoY), suggesting the recovery is driven by cost-cutting rather than market expansion. The stock is currently in a technical recovery phase (85.3% 1Y return) but remains fundamentally fragile due to negative profit margins of -70.41%.

Strengths
Exceptional liquidity with a Current Ratio of 6.60 and Quick Ratio of 5.40
Significant YoY EPS growth (+77.8%) indicating a reduction in losses
Strong 1-year price recovery (+85.3%) showing renewed investor interest
Risks
Negative revenue growth (-11.8% YoY and -11.59% Q/Q) indicating shrinking market share or demand
Severe profitability issues with a profit margin of -70.41%
High valuation relative to sales (P/S 6.49) despite declining revenue
STAA BEARISH

STAA exhibits severe fundamental weakness as evidenced by a critical Piotroski F-Score of 1/9, indicating a significant deterioration in financial health. While the company maintains a strong liquidity position (Current Ratio 4.55) and impressive gross margins (76.19%), it is unable to translate revenue growth into profitability, with a profit margin of -33.60%. The stock is currently trading at $25.08, which is a premium to the analyst target price of $21.11. Despite a favorable PEG ratio of 0.76, the lack of earnings stability and a bearish technical trend outweigh the growth potential.

Strengths
Strong gross margins of 76.19% indicating high product value
Excellent liquidity with a current ratio of 4.55
Very low leverage with a Debt/Equity ratio of 0.11
Risks
Severe financial health deterioration (Piotroski F-Score 1/9)
Negative profitability with a profit margin of -33.60%
Current price ($25.08) is significantly above the analyst target price ($21.11)

Compare Another Pair

MRVI vs STAA: Head-to-Head Comparison

This page compares Maravai LifeSciences Holdings, Inc. (MRVI) and STAAR Surgical Company (STAA) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile